Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes

Learn more about:
Related Clinical Trial
Clinical Profile of Neonates Having Patent Ductus Arteriosus Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes

Official Title

Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes

Brief Summary

      Patent ductus arteriosus (PDA), very common in preterm infants, is the delayed closure of a
      fetal blood vessel that limits blood flow through the lungs. PDA is associated with mortality
      and harmful long term outcomes including chronic lung disease and neurodevelopmental delay.
      Although, treatments to close PDA likely benefit some infants, widespread routine treatment
      of all preterm infants with PDA may not improve important outcomes. Left untreated, most PDAs
      close spontaneously. Thus, PDA treatment is increasingly controversial and varies markedly
      between hospitals and individual providers. The relevant and still unanswered clinical
      question is not whether to treat all preterm infants with PDA, but whom to treat and when.
      Treatment detriments may outweigh benefits, since all forms of deliberate PDA closure have
      potential adverse effects, especially in infants destined for early, spontaneous PDA closure.
      Unfortunately, clinicians cannot currently predict in the 1st month which infants are at
      highest risk for persistent PDA, and which combination of clinical risk factors,
      echocardiographic (echo) measurements, and serum biomarkers may best predict PDA-associated
      harm. The American Academy of Pediatrics has acknowledged early identification of infants at
      high-risk from PDA as a key research goal for informing future PDA-treatment effectiveness

      Our objective is to use a prospective cohort of untreated infants with PDA to predict
      spontaneous ductal closure timing and identify echo measurements and biomarkers that are
      present in the 1st postnatal month and associated with long-term impairment. Our central
      hypothesis is that these risk factors can be determined to inform appropriate clinical
      treatments when necessary. Clinical, serum and urine biomarkers (BNP, NTpBNP, NGAL, H-FABP),
      and echo variables sequentially collected during each of the first 4 postnatal weeks will be
      examined. In addition myocardial deformation imaging (MDI) and tissue Doppler imaging (TDI),
      innovative echo methods, will facilitate the quantitative evaluation of myocardial
      performance. Aim 1 will estimate the probability of spontaneous PDA closure and predict the
      timing of ductal closure using echo, biomarker, and clinical predictors. Aim 2 will specify
      which echo predictors and biomarkers are associated with mortality and severity of
      respiratory illness at 36-weeks PMA. Aim 3 will identify which echo predictors and biomarkers
      are associated with 22- to 26-month neurodevelopment. All models will be validated in a
      separate cohort. This project will significantly contribute to clinical outcomes and PDA
      management by reducing unnecessary and harmful overtreatment of infants with a high
      probability of early spontaneous PDA closure, and will permit the development of
      outcomes-focused trials to examine the effectiveness of PDA closure in those "high-risk"
      infants most likely to receive benefit.

Study Type

Observational [Patient Registry]

Primary Outcome

Patent ductus arteriosus (PDA) closure documented via echocardiogram by 36-weeks postmenstrual age (PMA) (binary)

Secondary Outcome

 Mortality by 36-weeks PMA (binary)


Patent Ductus Arteriosus

Study Arms / Comparison Groups

 Primary Study Cohort
Description:  450 Infants


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

April 1, 2019

Completion Date

December 2024

Primary Completion Date

December 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Born between 23-weeks + 0 days (23_0/7 wks) and 29-weeks + 6 days (29_6/7 wks)
             gestation, inclusive

          -  Admitted to a study neonatal intensive care unit (NICU) within 72-hours of birth

          -  PDA noted on initial screening echo at <72 postnatal hours

        Exclusion Criteria:

          -  Life-threatening congenital abnormalities, including congenital heart disease (other
             than PDA or small atrial septal defects/patent foramen ovale/muscular VSD)

          -  Parents have chosen to allow natural death (placed a do not resuscitate order)




N/A - 72 Hours

Accepts Healthy Volunteers



Jonathan L Slaughter, MD, MPH, 1-614-355-6643, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party

Principal Investigator

Study Sponsor

Nationwide Children's Hospital


 National Heart, Lung, and Blood Institute (NHLBI)

Study Sponsor

Jonathan L Slaughter, MD, MPH, Principal Investigator, Nationwide Children's Hospital/The Ohio State University

Verification Date

July 2020